{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:45:30Z","timestamp":1782726330589,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-180379"],"award-info":[{"award-number":["PJT-180379"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-183934"],"award-info":[{"award-number":["PJT-183934"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    BRAF V600 inhibitors are clinically approved for the treatment of BRAF\n                    <jats:sup>V600<\/jats:sup>\n                    -mutant melanoma in combination with a MEK inhibitor, but are ineffective in other melanoma subtypes. Moreover, pan-RAF inhibitors, such as belvarafenib, when combined with MEK inhibitors (cobimetinib), have promising but limited efficacy in non-\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutant melanomas. Here, we report that the mTOR inhibitor sapanisertib improves the efficacy of combined belvarafenib and cobimetinib therapy in\n                    <jats:italic>NRAS<\/jats:italic>\n                    ,\n                    <jats:italic>NF1<\/jats:italic>\n                    , and\n                    <jats:italic>KIT<\/jats:italic>\n                    -mutant melanomas. Mechanistically, sapanisertib combined with belvarafenib and cobimetinib suppressed ATF4 expression and its target gene MTHFD2 while inducing DNA damage, revealing a previously underappreciated role of the ATF4-MTHFD2 axis in DNA damage repair and drug response. Human and murine models resistant to combined belvarafenib and cobimetinib exhibited elevated levels of ATF4 and MTHFD2 and were sensitive to sapanisertib. This study provides promising treatment opportunities for patients with non-\n                    <jats:italic>BRAF<\/jats:italic>\n                    -mutant melanomas, or those who relapse following belvarafenib and cobimetinib combination therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08836-5","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:25:15Z","timestamp":1778037915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathway"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-4190","authenticated-orcid":false,"given":"Feiyang","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-5317","authenticated-orcid":false,"given":"Fan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7585-1593","authenticated-orcid":false,"given":"Harinee","family":"Srikannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0176-9407","authenticated-orcid":false,"given":"Elizabeth M.","family":"Guettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Mukeba-Harchies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krikor","family":"Bijian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Journe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9845-4603","authenticated-orcid":false,"given":"April A. N.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Orthwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6350-0227","authenticated-orcid":false,"given":"Sonia Victoria","family":"del Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"8836_CR1","doi-asserted-by":"crossref","unstructured":"Prabhu SA, Moussa O, Miller WH Jr, Del Rincon SV. The MNK1\/2-eIF4E axis as a potential therapeutic target in melanoma. Int J Mol Sci. 2020;21:4055.","DOI":"10.3390\/ijms21114055"},{"key":"8836_CR2","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"The Cancer Genome Atlas Network","year":"2015","unstructured":"The Cancer Genome Atlas NetworkGenomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"8836_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140:209\u201321.","journal-title":"Cell"},{"key":"8836_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"17","author":"Z Karoulia","year":"2017","unstructured":"Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer. 2017;17:676\u201391.","journal-title":"Nat Rev Cancer"},{"key":"8836_CR5","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.22.02322","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Dummer R, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Contribution of MEK inhibition to BRAF\/MEK inhibitor combination treatment of BRAF-mutant melanoma: Part 2 of the randomized, open-label, Phase III COLUMBUS trial. J Clin Oncol. 2023;41:4621\u201331.","journal-title":"J Clin Oncol"},{"key":"8836_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431\u20135.","journal-title":"Nature"},{"key":"8836_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427\u201330.","journal-title":"Nature"},{"key":"8836_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","volume":"28","author":"SB Peng","year":"2015","unstructured":"Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, et al. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell. 2015;28:384\u201398.","journal-title":"Cancer Cell"},{"key":"8836_CR9","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1158\/1078-0432.CCR-17-3384","volume":"24","author":"M Dankner","year":"2018","unstructured":"Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, et al. Dual MAPK inhibition is an effective therapeutic strategy for a subset of Class II BRAF mutant melanomas. Clin Cancer Res. 2018;24:6483\u201394.","journal-title":"Clin Cancer Res"},{"key":"8836_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102238","volume":"99","author":"T Randic","year":"2021","unstructured":"Randic T, Kozar I, Margue C, Utikal J, Kreis S. NRAS mutant melanoma: towards better therapies. Cancer Treat Rev. 2021;99:102238.","journal-title":"Cancer Treat Rev"},{"key":"8836_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41586-021-03515-1","volume":"594","author":"I Yen","year":"2021","unstructured":"Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature. 2021;594:418\u201323.","journal-title":"Nature"},{"key":"8836_CR12","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2021.39.15_suppl.3007","volume":"39","author":"SJ Shin","year":"2021","unstructured":"Shin SJ, Lee J, Kim TM, Kim J-S, Kim YJ, Hong YS, et al. A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion. J Clin Oncol. 2021;39:3007.","journal-title":"J Clin Oncol"},{"key":"8836_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nm.4091","volume":"22","author":"TG Bivona","year":"2016","unstructured":"Bivona TG, Doebele RC. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med. 2016;22:472\u20138.","journal-title":"Nat Med"},{"key":"8836_CR14","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1038\/s41388-021-01911-5","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, et al. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. 2021;40:5590\u20139.","journal-title":"Oncogene"},{"key":"8836_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/2159-8290.CD-13-0279","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014;4:69\u201379.","journal-title":"Cancer Discov"},{"key":"8836_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell. 2010;18:683\u201395.","journal-title":"Cancer Cell"},{"key":"8836_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature14336","volume":"520","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520:368\u201372.","journal-title":"Nature"},{"key":"8836_CR18","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17:1374\u201395.","journal-title":"EMBO Rep"},{"key":"8836_CR19","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.celrep.2017.04.042","volume":"19","author":"Y Park","year":"2017","unstructured":"Park Y, Reyna-Neyra A, Philippe L, Thoreen CC. mTORC1 balances cellular amino acid supply with demand for protein synthesis through post-transcriptional control of ATF4. Cell Rep. 2017;19:1083\u201390.","journal-title":"Cell Rep"},{"key":"8836_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21549-x","volume":"12","author":"C Yang","year":"2021","unstructured":"Yang C, Tian C, Hoffman TE, Jacobsen NK, Spencer SL. Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling. Nat Commun. 2021;12:1747.","journal-title":"Nat Commun"},{"key":"8836_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature10912","volume":"485","author":"AC Hsieh","year":"2012","unstructured":"Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485:55\u201361.","journal-title":"Nature"},{"key":"8836_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000291","volume":"3","author":"KN Moore","year":"2018","unstructured":"Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, et al. Phase I study of the investigational oral mTORC1\/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. ESMO Open. 2018;3:e000291.","journal-title":"ESMO Open"},{"key":"8836_CR23","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cpdd.808","volume":"9","author":"C Patel","year":"2020","unstructured":"Patel C, Goel S, Patel MR, Rangachari L, Wilbur JD, Shou Y, et al. Phase 1 study to evaluate the effect of the investigational anticancer agent sapanisertib on the QTc interval in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2020;9:876\u201388.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"8836_CR24","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932\u201340.","journal-title":"Oncogene"},{"key":"8836_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","volume":"24","author":"N Perurena","year":"2024","unstructured":"Perurena N, Situ L, Cichowski K. Combinatorial strategies to target RAS-driven cancers. Nat Rev Cancer. 2024;24:316\u201337.","journal-title":"Nat Rev Cancer"},{"key":"8836_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.3361","volume":"47","author":"M Krauthammer","year":"2015","unstructured":"Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 2015;47:996\u20131002.","journal-title":"Nat Genet"},{"key":"8836_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/leu.2012.276","volume":"27","author":"MR Janes","year":"2013","unstructured":"Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia. 2013;27:586\u201394.","journal-title":"Leukemia"},{"key":"8836_CR28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/ng1634","volume":"37","author":"PB Gupta","year":"2005","unstructured":"Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, et al. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet. 2005;37:1047\u201354.","journal-title":"Nat Genet"},{"key":"8836_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/ijc.2910390324","volume":"39","author":"DC Bennett","year":"1987","unstructured":"Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer. 1987;39:414\u20138.","journal-title":"Int J Cancer"},{"key":"8836_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101028","volume":"23","author":"I Nagasawa","year":"2020","unstructured":"Nagasawa I, Koido M, Tani Y, Tsukahara S, Kunimasa K, Tomida A. Disrupting ATF4 expression mechanisms provides an effective strategy for BRAF-targeted melanoma therapy. iScience. 2020;23:101028.","journal-title":"iScience"},{"key":"8836_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1112253","volume":"16","author":"G Neill","year":"2023","unstructured":"Neill G, Masson GR. A stay of execution: ATF4 regulation and potential outcomes for the integrated stress response. Front Mol Neurosci. 2023;16:1112253.","journal-title":"Front Mol Neurosci"},{"key":"8836_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/pcmr.12807","volume":"32","author":"V Petit","year":"2019","unstructured":"Petit V, Raymond J, Alberti C, Pouteaux M, Gallagher SJ, Nguyen MQ, et al. C57BL\/6 congenic mouse NRAS(Q61K) melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo. Pigment Cell Melanoma Res. 2019;32:829\u201341.","journal-title":"Pigment Cell Melanoma Res"},{"key":"8836_CR33","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/0008-5472.CAN-04-2970","volume":"65","author":"J Ackermann","year":"2005","unstructured":"Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 2005;65:4005\u201311.","journal-title":"Cancer Res"},{"key":"8836_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","volume":"19","author":"I Arozarena","year":"2019","unstructured":"Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19:377\u201391.","journal-title":"Nat Rev Cancer"},{"key":"8836_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41586-022-05242-7","volume":"610","author":"P Karras","year":"2022","unstructured":"Karras P, Bordeu I, Pozniak J, Nowosad A, Pazzi C, Van Raemdonck N, et al. A cellular hierarchy in melanoma uncouples growth and metastasis. Nature. 2022;610:190\u20138.","journal-title":"Nature"},{"key":"8836_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0051-4","volume":"2","author":"MC Wagle","year":"2018","unstructured":"Wagle MC, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. npj Precis Oncol. 2018;2:7.","journal-title":"npj Precis Oncol"},{"key":"8836_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40235-8","volume":"14","author":"R Sigaud","year":"2023","unstructured":"Sigaud R, Albert TK, Hess C, Hielscher T, Winkler N, Kocher D, et al. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas. Nat Commun. 2023;14:4533.","journal-title":"Nat Commun"},{"key":"8836_CR38","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/s41556-019-0415-1","volume":"21","author":"G Pathria","year":"2019","unstructured":"Pathria G, Lee JS, Hasnis E, Tandoc K, Scott DA, Verma S, et al. Translational reprogramming marks adaptation to asparagine restriction in cancer. Nat Cell Biol. 2019;21:1590\u2013603.","journal-title":"Nat Cell Biol"},{"key":"8836_CR39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017;170:17\u201333.","journal-title":"Cell"},{"key":"8836_CR40","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ccell.2021.05.015","volume":"39","author":"O Marin-Bejar","year":"2021","unstructured":"Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell. 2021;39:1135\u201349.e8.","journal-title":"Cancer Cell"},{"key":"8836_CR41","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","volume":"332","author":"WP Roos","year":"2013","unstructured":"Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013;332:237\u201348.","journal-title":"Cancer Lett"},{"key":"8836_CR42","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858\u201368.","journal-title":"J Biol Chem"},{"key":"8836_CR43","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.stemcr.2020.06.018","volume":"15","author":"L Yue","year":"2020","unstructured":"Yue L, Pei Y, Zhong L, Yang H, Wang Y, Zhang W, et al. Mthfd2 modulates mitochondrial function and DNA repair to maintain the pluripotency of mouse stem cells. Stem Cell Rep. 2020;15:529\u201345.","journal-title":"Stem Cell Rep"},{"key":"8836_CR44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature13236","volume":"510","author":"J Fan","year":"2014","unstructured":"Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. Quantitative flux analysis reveals folate-dependent NADPH production. Nature. 2014;510:298\u2013302.","journal-title":"Nature"},{"key":"8836_CR45","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrc3557","volume":"13","author":"JW Locasale","year":"2013","unstructured":"Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer. 2013;13:572\u201383.","journal-title":"Nat Rev Cancer"},{"key":"8836_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.nutr.012809.104810","volume":"30","author":"AS Tibbetts","year":"2010","unstructured":"Tibbetts AS, Appling DR. Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr. 2010;30:57\u201381.","journal-title":"Annu Rev Nutr"},{"key":"8836_CR47","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/s41388-018-0589-1","volume":"38","author":"T Nishimura","year":"2019","unstructured":"Nishimura T, Nakata A, Chen X, Nishi K, Meguro-Horike M, Sasaki S, et al. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. Oncogene. 2019;38:2464\u201381.","journal-title":"Oncogene"},{"key":"8836_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17512-x","volume":"11","author":"W Zhou","year":"2020","unstructured":"Zhou W, Yao Y, Scott AJ, Wilder-Romans K, Dresser JJ, Werner CK, et al. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nat Commun. 2020;11:3811.","journal-title":"Nat Commun"},{"key":"8836_CR49","doi-asserted-by":"crossref","unstructured":"Torrence ME, MacArthur MR, Hosios AM, Valvezan AJ, Asara JM, Mitchell JR, et al. The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals. eLife. 2021;10:e63326.","DOI":"10.7554\/eLife.63326"},{"key":"8836_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7527996","volume":"2022","author":"Y Gao","year":"2022","unstructured":"Gao Y, Feng L, Zhang L, Geng J, Zhang E. ATF4\/MYC regulates MTHFD2 to promote NSCLC progression by mediating redox homeostasis. Dis Markers. 2022;2022:7527996.","journal-title":"Dis Markers"},{"key":"8836_CR51","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s43856-025-01150-9","volume":"5","author":"BR Yavuz","year":"2025","unstructured":"Yavuz BR, Jang H, Nussinov R. Discovering anticancer drug target combinations via network-informed signaling-based approach. Commun Med. 2025;5:428.","journal-title":"Commun Med"},{"key":"8836_CR52","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/1535-7163.MCT-14-1093-T","volume":"14","author":"S Wang","year":"2015","unstructured":"Wang S, Chen XA, Hu J, Jiang JK, Li Y, Chan-Salis KY, et al. ATF4 gene network mediates cellular response to the anticancer PAD inhibitor YW3-56 in triple-negative breast cancer cells. Mol Cancer Ther. 2015;14:877\u201388.","journal-title":"Mol Cancer Ther"},{"key":"8836_CR53","doi-asserted-by":"crossref","unstructured":"Ord T, Ord D, Kaikkonen MU, Ord T. Pharmacological or TRIB3-mediated suppression of ATF4 transcriptional activity promotes hepatoma cell resistance to proteasome inhibitor bortezomib. Cancers. 2021;13:2341.","DOI":"10.3390\/cancers13102341"},{"key":"8836_CR54","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ncb2738","volume":"15","author":"J Han","year":"2013","unstructured":"Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J, et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol. 2013;15:481\u201390.","journal-title":"Nat Cell Biol"},{"key":"8836_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3694362","volume":"2018","author":"JK Freundt","year":"2018","unstructured":"Freundt JK, Frommeyer G, Wotzel F, Huge A, Hoffmeier A, Martens S, et al. The transcription factor ATF4 promotes expression of cell stress genes and cardiomyocyte death in a cellular model of atrial fibrillation. Biomed Res Int. 2018;2018:3694362.","journal-title":"Biomed Res Int"},{"key":"8836_CR56","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.aad0489","volume":"351","author":"I Ben-Sahra","year":"2016","unstructured":"Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016;351:728\u201333.","journal-title":"Science"},{"key":"8836_CR57","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fonc.2020.00658","volume":"10","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Leung GKK. More than a metabolic enzyme: MTHFD2 as a novel target for anticancer therapy? Front Oncol. 2020;10:658.","journal-title":"Front Oncol"},{"key":"8836_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s44324-024-00005-6","volume":"2","author":"N Pardo-Lorente","year":"2024","unstructured":"Pardo-Lorente N, Sdelci S. MTHFD2 in healthy and cancer cells: canonical and non-canonical functions. npj Metab Health Dis. 2024;2:3.","journal-title":"npj Metab Health Dis"},{"key":"8836_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09606-0","volume":"22","author":"L Zhu","year":"2022","unstructured":"Zhu L, Liu X, Zhang W, Hu H, Wang Q, Xu K. MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder. BMC Cancer. 2022;22:556.","journal-title":"BMC Cancer"},{"key":"8836_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/0008-5472.CAN-23-1290","volume":"84","author":"L Ramos","year":"2024","unstructured":"Ramos L, Henriksson M, Helleday T, Green AC. Targeting MTHFD2 to exploit cancer-specific metabolism and the DNA damage response. Cancer Res. 2024;84:9\u201316.","journal-title":"Cancer Res"},{"key":"8836_CR61","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.tips.2024.04.012","volume":"45","author":"R Nussinov","year":"2024","unstructured":"Nussinov R, Yavuz BR, Jang H. Anticancer drugs: How to select small molecule combinations? Trends Pharmacol Sci. 2024;45:503\u201319.","journal-title":"Trends Pharmacol Sci"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08836-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:05:12Z","timestamp":1782723912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08836-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8836"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08836-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Animal experiments were conducted according to the regulations established by the Canadian Council of Animal Care, and protocols approved by McGill University Animal Care and Use Committee (#2015-7672).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"600"}}